When Investors Panic, I Buy Eli Lilly

In the latest market turbulence, seasoned investor The Pragmatic Investor leader James Foord is doubling down on Eli Lilly and Company (NYSE: LLY), arguing that when others flee, the time to buy is now. Foord points to Lilly’s Q3 2025 results—where revenue surged a remarkable 54 % year‑over‑year—as evidence of the company’s strength amid economic uncertainty. At the heart of the bullish thesis: Lilly’s dominant position in the obesity and diabetes market. Products like Mounjaro and Zepbound are generating substantial international growth, and Lilly’s pipeline—including promising candidates like orforglipron—suggests a durable competitive moat. Foord also emphasizes Lilly’s manufacturing push and strong cash flow, positioning it as a relatively defensive play in volatile markets. That said, he cautions that regulatory risk and execution hurdles remain—yet he views conviction in Lilly as justified for long‑term investors. In short: while many retreat when the market panics, this investor sees Lilly not as a risk but as a reward. #EliLilly #PharmaInvesting #BiotechGrowth #MarketVolatility #SlimScan #GrowthStocks #CANSLIM